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Abstract
Background: In South America, the highest incidence of primary liver cancer is observed in Peru. However, national
estimations on hepatocellular carcinoma incidence and mortality are approximated using aggregated data from
surrounding countries. Thus, there is a lack of tangible information from Peru that impairs an accurate description of the
local incidence, presentation, and outcomes of hepatocellular carcinoma. The present study attempts to fill this gap and
assesses the clinical epidemiology of hepatocellular carcinoma in this country.
Methods: A retrospective cohort study was conducted by analysing the medical charts of 1,541 patients with hepatocellular
carcinoma admitted between 1997 and 2010 at the Peruvian national institute for cancer. The medical records including
liver function, serologic status, and tumor pathology and stage were monitored. Statistical analyses were performed in order
to characterize tumor presentation according to demographic features, risk factors, and regional origin.
Results: Surprisingly, the age distribution of the patient population displayed bimodality corresponding to two distinct age-
based subpopulations. While an older group was in keeping with the age range observed for hepatocellular carcinoma
around the world, a younger population displayed an abnormally juvenile mean age of 25.5 years old. In addition, each
subpopulation displayed age-specific pathophysiological and clinical characteristics.
Conclusions: The analysis suggests two different age-specific natural histories of hepatocellular carcinoma in the Peruvian
patient population. This otherwise unusual tumor process that is ongoing in younger patients leads to the hypothesis that
there may be a Peru-endemic risk factor driving hepatocarcinogenesis in the local population.
Citation: Bertani S, Pineau P, Loli S, Moura J, Zimic M, et al. (2013) An Atypical Age-Specific Pattern of Hepatocellular Carcinoma in Peru: A Threat for Andean
Populations. PLoS ONE 8(6): e67756. doi:10.1371/journal.pone.0067756
Editor: Jung Weon Lee, Seoul National University, Republic of Korea
Received January 29, 2013; Accepted May 22, 2013; Published June 28, 2013
Copyright:  2013 Bertani et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: stephane.bertani@ird.fr
. These authors contributed equally to this work.
Introduction
Hepatocellular carcinoma (HCC), the main form of primary
liver cancer, is the sixth most common malignancy and the third
leading cause of tumor-related death in the world [1,2]. Global
clinical epidemiology of HCC defines a dominant patient profile
corresponding grossly to males over 40 years old [3,4]. The
incidence rate of HCC has doubled worldwide during the last two
decades, with nearly 85% of the recorded cases occurring in
developing countries [1,2,5]. The greatest burden of HCC is borne
in sub-Saharan Africa and eastern Asia, where chronic infection
with hepatitis B virus (HBV) is highly endemic [1–6].
Reference reviews on the worldwide burden of HCC have
constantly neglected to include the epidemiology of the disease in
South America creating a gap between the existing epidemiolog-
ical situation on the field and the global epidemics of HCC
described in literature [2–5]. While the incidence rate of primary
liver cancer in South America is considered low, the epidemiology
of HCC on this continent displays intriguing characteristics. For
example, the sex ratio of HCC is more balanced in South America
than in any other regions of the world [1]. Nonetheless, with the
exception of Brazil, a lack of information on primary liver cancers
impairs an accurate description of HCC outcomes at both national
and continental levels [1]. Incidence and mortality data for HCC
in South America are often gathered from sparse cancer registries,
and estimations are thus approximated using aggregated data from
surrounding countries [1].
Peru is considered to have the highest incidence of primary liver
cancer in South America [1]. Very few studies have been
conducted concerning the clinical epidemiology of HCC among
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the Peruvian population; therefore our knowledge of the disease in
Peru is lacking. To address this issue, we performed a retrospective
study on Peruvian patients diagnosed with HCC between 1997
and 2010. Specifically, this study was designed to assess the clinical
epidemiology of Peruvian patient population with HCC in a large
well-characterized cohort.
Methods
2.1. Study Design
The current study was conducted retrospectively within a
cohort assembled by analysing the medical records of 1,541
patients admitted for HCC at the Peruvian national hospital for
cancer (INEN) between January 1997 and December 2010.
Written consent was given by the patients for their information to
be stored in the Department of Cancer Statistics and Epidemi-
ology of INEN, and used for research. Human Subjects
committees at both the INEN (Peru) and the Institut Pasteur
(France) approved this study.
Under the Peruvian Ministry of Health, INEN is the health care
institution in charge of the management of neoplastic diseases at
the national level [7]. As a public hospital, INEN treats patients
regardless of age, sex, ethnicity, place of residence, economic
status, and health care coverage. The centralization of the
Peruvian health care system means that INEN serves as a national
hub for neoplasm management and handles a large ratio of cancer
cases from across the nation, providing a valuable environment for
assessing the clinical-epidemiological context of HCC in Peru [7].
The vital records (i.e. sex, age, birthplace, place of residence,
social situation, and family health history), personal medical
history, liver function, and physiological, biochemical, and
immunological status of patients with HCC were monitored for
the duration of their hospital stay. The overall patient population
was 1,541, corresponding to the whole patient population with
HCC admitted at INEN between 1997 and 2010. However, due
to the context of limited resources in Peru, INEN could not
routinely examine all clinical specimens for every biomedical
analysis, notably for hepatitis infection and tumor grading [8]. The
opportunity of each biomedical analysis was then at the own
discretion of the practitioner taking into account the patient’s best
interests. The available cohorts for the different pathophysiological
parameters analyzed from the initial 1,541 patient’s number are
presented (Table 1).
2.2. Hospital Procedure and Monitored Parameters
Individuals suspected to have malignant liver neoplasm were
managed through the Department of Abdominal Surgery of
INEN. The vital records and medical history of these patients were
documented during their first consultation. Detection and
preliminary clinical characterization of the tumor were carried
out by both physical examination and non-invasive diagnostic
imaging, i.e. computed axial tomography and abdominal ultra-
sounds. Cancer staging was classified according to the TNM and
the Barcelona-Clinic Liver Cancer (BCLC) staging systems [9].
Pathologists assessed the type of cancer cells on hematoxylin–
eosin-stained liver biopsy sections and scored the grade of tumor
(G1–3) according to the recommendations of the American Joint
Committee on Cancer [10]. Hepatoblastoma and intrahepatic
cholangiocellular carcinoma cases were not included in the study.
Liver function tests were conducted by serum quantitation of
gamma-glutamyl transpeptidase, alkaline phosphatase, total and
direct bilirubin, albumin, and alanine and aspartate transaminas-
es. Tumor marker alpha-fetoprotein (AFP) was monitored for its
serum concentration (seroAFP) by radioimmunoassay (Roche)
during the patient’s hospital stay. In parallel, infections with HBV
and hepatitis C virus (HCV) were assessed from serum of HCC
patients by electrogenerated chemiluminescence assay using
antibodies against HBV surface antigen (HBsAg), anti-HBs
antibody, anti-HBc IgG and IgM, HBe antigen, and anti-HCV
antibody (all from Roche).
Patients with a Child-Pugh score of A were treated by anatomic
liver resection, i.e. systematic removal of the tumoral liver
segments confined by portal branches, to ensure tumor-free
margins [11–13]. The surgical report recorded the size, location,
and appearance of the tumor, as well as additional pathological
observations (e.g. cirrhotic, multinodular, and/or metastatic
status). Patient survival was followed-up prospectively by periodic
medical consultations or phone interviews.
2.3. Statistical Analysis
Age distribution was analyzed using a Gaussian mixture model
for detecting bimodality and calculating the bimodality index (BI)
and the moment of mixture (MM) [14–16]. Description of
variables was reported by median (inter-quartile range) or mean
(95% confidence interval) depending on the normality of the
distribution assessed by the Shapiro-Wilks test [17]. Bivariable
comparisons were conducted by parametric or non-parametric
tests depending on the normality of the distribution. A multivar-
iable analysis was performed in order to identify the age-adjusted
effect. Linear regressions were used to model the dispersion of
normally distributed continuous variables. Simple exact and
multinomial logistic regressions were used to model the outcomes
with dichotomized age (i.e. #44 vs. .44) as the predictor after
patients’ geographical precedence and seasonal adjustments.
Multidimensional outliers were assessed with the Hadi test and
nested models were compared with the likelihood ratio test [18].
The tumor size was transformed with the square root function in
order to make it normally distributed. Patient survival rates were
analyzed using the Kaplan–Meier method and the log-rank test
was used to compare survival distributions [19–21]. Statistical
analyses were performed with a 5% significance level using Stata
Statistical Software: Release 11 (College Station, TX: StataCorp
LP) and SPSS 13.0 predictive analytics software (SPSS Inc.).
Patient places of origin (birthplace) were spatially aggregated
according to a standard deviation classification of mean age, and
choropleth mapping was performed using Philcarto mapping
software [22].
Results
The INEN admitted an average of 112 HCC cases per year
(Figure 1A). The mean age of the patients was 44.8621.9 years old
(Table 1). The age distribution of the HCC patients displayed
bimodality with two frequency modes corresponding to two
distinct age-based subpopulations (BI = 1.95) (Figure 1B,C and
Table 1). The MM of the two modes corresponding to the in-
between age was calculated at 44.8 years old (Figure 1B). The
patient distribution for the two modes was 778 for the group
younger or equal to age 44 (#44 group), and 763 the group older
than age 44 (.44 group) (Figure 1B,C and Table 1). The
respective mean and median ages were 25.569.5 and 25 in the
#44 group, and 64.5610.4 and 65 in the .44 group (Figure 1B
and Table 1). The overall sex ratio was 1.6, with 61.1% and
38.9% of men and women, respectively (Table 1). The age-specific
sex ratios were significantly different with 2 and 1.2 in the #44
group and the .44 group, respectively (P,0.0001) (Figure 1C and
Table 1).
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Patients were hospitalized with an average tumor size of
12.365.6 cm-diameter. The age-specific average tumor size was
13.165.7 and 11.465.4 cm-diameter for the #44 and .44
groups, respectively. The tumor size was transformed with the
square root function in order to make it normally distributed for
linear regression analysis. #44 and .44 groups displayed
significant difference in tumor dimension (P,0.0001). A higher
prevalence of distant metastases was recorded in the #44 group
(P= 0.007), while multinodular HCCs were preponderant in the
.44 group (P= 0.015) (Table 1). A significant ratio of undiffer-
entiated or poorly differentiated tumors with high grades (G3)
among the #44 group compared to the .44 group (P= 0.037)
(Table 1). The tumor size standardization demonstrated a drastic
6.7 fold elevation of AFP in the #44 group with
29,12463,382 ng/ml/tumor-cm, compared to the
4,3316311 ng/ml/tumor-cm of the .44 group (P,0.0001)
(Figure 2A). Although it remained remarkably low in both
subpopulations, the prevalence of associated cirrhosis was signif-
icantly higher in the .44 group, showing 17.1% vs. 5.1% in the
#44 group (P,0.0001) (Figure 2B and Table 1). Linear regression
Table 1. Patient characteristics at baseline.
Number of patients
(#44 and .44 groups)
Number of patients
(#44 group)
Number of patients
(.44 group) P-value
Overall cohort 1,541 (100%) 778 (50.5%) 763 (49.5%) –
Age Mean6SEM 44.8621.9 25.569.5 64.5610.4 –
Median 44 25 65
Range [0–89] [0–44] [45–89]
Sex Male 942 (61.1%) 520 (66.8%) 422 (55.3%)
Female 599 (38.9%) 258 (33.2%) 341 (44.7%)
Total 1,541 (100%) 778 (100%) 763 (100%) ,0.0001*
Tumor grade{ G1 47 (13.7%) 22 (14.3%) 25 (13.2%)
G2 226 (65.7%) 86 (55.8%) 140 (73.7%)
G3 71 (20.6%) 46 (29.9%) 25 (13.2%)
Total 344 (100%) 154 (100%) 190 (100%) 0.037**
Cirrhosis Yes 163 (11%) 38 (5.1%) 125 (17.1%)
No 1,316 (89%) 709 (94.9%) 607 (82.9%)
Total 1,479 (100%) 747 (100%) 732 (100%) ,0.0001*
Hepatitis B Yes 453 (50.1%) 365 (71%) 88 (22.5%)
No 452 (49.9%) 149 (29%) 303 (77.5%)
Total 905 (100%) 514 (100%) 391 (100%) ,0.0001*
Hepatitis C Yes 29 (4.7%) 9 (2.7%) 20 (6.8%)
No 593 (95.3%) 319 (97.3%) 273 (93.2%)
Total 622 (100%) 328 (100%) 293 (100%) 0.021*
Hepatitis B+C Yes 8 (1.4%) 5 (1.6%) 3 (1.1%)
No 583 (98.6%) 301 (98.4%) 282 (98.9%)
Total 591 (100%) 306 (100%) 285 (100%) NS*
Nodule(s) = 1 450 (41.4%) 246 (38.3%) 204 (45.8%)
.1 638 (58.6%) 397 (61.7%) 241 (54.2%)
Total 1,088 (100%) 643 (100%) 445 (100%) 0.015*
Metastasis Yes 430 (30.1%) 244 (33.3%) 186 (26.7%)
No 1,000 (69.9%) 489 (66.7%) 511 (73.3%)
Total 1,430 (100%) 733 (100%) 697 (100%) 0.007*
Operation Yes 298 (19.3%) 159 (20.4%) 139 (18.2%)
No 1,243 (80.7%) 619 (79.6%) 624 (81.8%)
Total 1,541 (100%) 778 (100%) 763 (100%) NS*
Recurrence` Yes 132 (44.7%) 76 (48.7%) 56 (40.3%)
No 163 (55.3%) 80 (51.3%) 83 (59.7%)
Total 295 (100%) 156 (100%) 139 (100%) NS*
#44 and .44 groups are defined as patients below or equal age 44 and those above age 44, respectively. Mean values are presented with 6 standard errors of the
means (SEM). Percentages are expressed as ratio of the total patient population for the considered parameter. P-values were obtained by exact simple (*) or multinomial
(**) logistic regression analysis, modelling the specific outcomes with age (#44 groups vs. .44 group) after geographical and seasonal adjustments. NS: not significant.
{Tumor grades were defined as follow: well differentiated (G1), moderately differentiated (G2), and poorly differentiated (G3).
`The data on recurrence are presented for patients who developed a new HCC within the following 12 months after surgical intervention.
doi:10.1371/journal.pone.0067756.t001
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analyses on the quantitation of gamma-glutamyl transpeptidase,
alkaline phosphatase, bilirubin, albumin, and transaminases did
not demonstrated neither deviant values nor significant difference
between the #44 and .44 groups (P.0.05).
While the rate of HBV infection was substantially higher in the
younger population (P,0.0001), the HCV infection rate was
significantly higher in the older one (P= 0.021) (Figure 2B and
Table 1). Logistic regression analyses showed that cancer history in
both nuclear and extended families was not a discriminating trait
between the two age-based subpopulations (P= 0.123). Overall,
46.2% of patients did not present any associated risk factor, such
as cirrhosis or hepatitis (Figure 2B).
Among the 298 patients selected for surgery, 44.7% developed a
recurrence within 12 months following anatomic liver resection
(Table 1). The survival rate at 5 years following the intervention
was not significantly different between the two subpopulations,
with 25.9% and 19.9% for the #44 and .44 groups, respectively
(P= 0.104) (Figure 2C–E and Table 1).
Mapping patients’ place of origin revealed geographic dispar-
ities in age-based HCC development (Figure 3). While the
youngest mean ages were recorded in the inland Andean regions
with the lowest value in Apurimac region [31.6617.9 years old
(Figure 3, region number 3)], the oldest mean ages were monitored
in the coastal and southern regions, culminating in La Libertad
region [61.6619.3 years old (Figure 3, region number 13)].
Discussion
This study sought to characterize the clinical-epidemiological
situation of HCC in Peru, the country in South America with
highest incidence of primary liver cancers [1]. The study was
conducted by retrospectively analysing the clinical records of
patients with HCC hospitalized at INEN between 1997 and 2010.
During this period, INEN admitted over 100 cases of HCC per
year, about 25% of the national incident cases of primary liver
cancer according to the GLOBOCAN 2008 estimates (Figure 1A
and Table 1) [1]. Patients hospitalized with HCC were mostly low-
and medium-income patients with poor health care coverage.
Positioned at a central hub for neoplasm treatment in Peru, INEN
received patients from all 25 administrative regions of the country
providing an ad rem nationwide sampling perspective (Figure 3).
It is generally admitted that HCC occurs mostly in men over 40
years old [1,3,5]. In high incidence areas of West Africa and East
Asia, age-specific incidence distributions are unimodal and
increase after 40 years of age to culminate around 55 [5]. In our
study, the age-specific distribution of the patients exhibited an
astonishing bimodal pattern corresponding to two distinct age-
based subpopulations (Figure 1B,C). This unusual feature
prompted us to analyze subsequently the cohort according to
age by dividing the series in two distinct subsets below and above
age 44, which corresponds to the MM of the bimodal Gaussian
distribution. Between 1997 and 2010, the proportions of these two
age-based subpopulations were similar with the #44 and .44
groups representing respectively 50.5% and 49.5% of the overall
patient population (Table 1). A careful examination of the #44
and .44 group distributions on an annual basis did not show any
noticeable evolution of age repartition over the period; indicating
that the presence of young HCC patients is a constitutive feature
of the disease in Peru. While the older group was in keeping with
the age range observed over the world, the #44 group with a
mean age of 25 corresponded to an epidemiologically deviant
population of patients with regard to the world standard of HCC
development [1–6]. A study conducted in Mozambique in 1985
showed a significant HCC incidence among young patients,
Figure 1. Distribution of the patients admitted at INEN with
HCC from January 1997 to December 2010. Histograms show the
distribution of patients over the period in function of their diagnosis
date (A), age at the time of diagnosis (B,C), and gender (C). X-axes
display date (annual interval) (A) and age (3-year interval) (B,C); Y-axes
display fraction (A,B) and frequency (Freq) (C) of the total number of
patients (N = 1,541). Straight line represents the histogram curve fitting
with a Gaussian mixture function (BI = 1.95; MM: 44.8) (B). Female and
male patients are represented in light and dark greys, respectively (C).
doi:10.1371/journal.pone.0067756.g001
Hepatocellular Carcinoma in Peru
PLOS ONE | www.plosone.org 4 June 2013 | Volume 8 | Issue 6 | e67756
however they were included within a unimodal age distribution
and a clear distinction between two age-based subpopulations was
not established [23].
In Peru, a large majority of patients were diagnosed with a
tumor exceeding 10 cm in diameter. The consistent detection of
advanced HCC may reflect a restricted access to health care in the
country [8]. However, this situation is most likely due to several
features intrinsic to the type of liver disease that affects Peruvian
patients. Amazingly, proportions of HCC patients with and
without liver cirrhosis in Peru (11% and 89%, respectively) are
inverted when compared to the European and North American
standards, in which rates of up to 80–90% of cirrhosis-associated
HCC are observed (Table 1) [3–6]. In addition, almost half the
patients lack a bona fide risk factor (Figure 2B). Both characteristics
imply that in most Peruvian cases, HCC is diagnosed without any
prodromes or long-lasting liver disease enabling the prediction of
an ongoing tumorigenic process. As Peruvian HCC develops
essentially in healthy liver, the clinical symptoms commonly
associated with an advanced malignant tumor represent the
inaugural signs of hepatic neoplasia in Peru. Such a situation is
exceptional in Asia, Europe, and North America, whereas it is the
presentation of a minority of HCC cases in Africa [2–6,9].
Current staging systems, e.g. the TNM and BCLC classifica-
tions, seem to be inadequate for the Peruvian context of HCC, as
they have been validated by surgically oriented groups from the
northern hemisphere treating patients in an utterly different
Figure 2. Pathophysiological parameters associated with HCC in the two age-based patient populations. (A) Box plots show quartile
distribution of seroAFP in ng/ml in #44 group (grey box; N = 631) and .44 group (black box; N = 558). *P,0.0001 vs. .44 group (i.e. adjusted
multiple linear regression analysis). (B) Estimated fractions (%) of HCC attributable to HBV and HCV etiologies (VirEtiol) or non-viral cirrhosis (CIR), or
non-attributable to bona fide risk factor (ND) in #44 females (hatched grey) and males (solid grey) and .44 females (hatched black) and males (solid
black). (C) Overall Kaplan–Meier survival curve for patients selected for anatomic liver resection (N = 298). (D) Age-based Kaplan–Meier survival curves
for the #44 group (grey curve; N = 156) and the .44 group (black curve; N = 139). (E) Kaplan–Meier survival rates (%) monitored for the 2 age-based
populations at 1, 3, and 5 years following hepatectomy. Median survival is presented as month (upper – lower interquartile range).
doi:10.1371/journal.pone.0067756.g002
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pathophysiological context [9,24,25]. The generally late detection
of HCC in Peru resulted in merely 20% of the #44 patients being
selected for tumor resection over the period (Table 1). The
aggressiveness of HCC in younger patients was illustrated by the
higher percentage of early recurrence and lower 5-year survival
rate among #44 group of patients which underwent resection of
large HCC, as compared to previous studies (Figure 2D,E and
Table 1) [26–30]. Such astounding figures highlight the urgent
need for a population-wide screening program of HCC in Peru.
Interestingly, the #44 and .44 groups displayed age-specific
pathophysiological characteristics (Figure 2A,B and Table 1). The
ratios of affected men to affected women were significantly higher
in the younger population than in the older one with 2 and 1.2,
respectively (Figure 1C and Table 1). Withal, sex ratio in both
subpopulations appeared to be more balanced than those observed
elsewhere in the world (up to 7 in selected populations) [1,26].
Besides, metastasis-associated HCC occurred significantly more in
the younger population and development of intrahepatic multi-
nudolar tumors took place preferentially in the older group
(Table 1). Albeit surprisingly low, the rate of cirrhosis was higher in
the .44 group than in the #44 group with 17% and 5%,
respectively (Figure 2B and Table 1) [3–6]. The biological base of
such situations remains unexplained and it is difficult to determine
whether the outcome is due to an explosive tumor process that
does not require chronic insult of liver tissue to develop.
Otherwise, it may be the consequence of a particular resistance
of the Peruvian populations to cirrhogenic conditions.
The seroAFP was exceedingly high in the #44 group compared
with the .44 group (Figure 2A). The mean of AFP concentration
for the #44 group reached 332,000 ng per millilitre, while AFP
biosynthesis is usually augmented during HCC up to hundreds or
thousands ng per millilitre [31–33]. AFP is transiently produced
during embryonic development in the establishment of the
endodermal cell lineages (e.g. hepatocytes) and its expression is
reactivated during HCC development [31–37]. Carcinogenesis
shares underlying molecular mechanisms with cellular differenti-
ation [38–41]. Homeotic genes that function in cell specialization
by regulating differentiation marker expression such as AFP are
misregulated in cancer [42–45]. The tremendously high seroAFP
monitored in the#44 group therefore supports the hypothesis that
aberrant activity of the genes involved in the cell identity and
homeostasis drives hepatocarcinogenesis in this patient subpopu-
lation. This hypothesis is reinforced by the predominance of
undifferentiated and poorly differentiated hepatic cancer cells
encountered in the #44 group (Table 1).
Multiple factors can be responsible of HCC development,
including genetics, infectious agents, comorbid conditions, and
environmental exposures [6,46–51]. Each of these factors has a
specific impact on the development of liver cancer and influences
the natural course of the neoplasm, both at cellular and
pathophysiological levels [33,51]. As in western Africa and eastern
Asia, the major of risk factors identified in Peru is the infection
with HBV (Figure 2B) [3–6]. A large majority of HBV strains
found in Peru belongs to subgenotype F1 and present peculiar
mutations and deletions in the viral polymerase and PreS regions,
respectively [52]. However, the tumorigenic potential of these
strains remains unknown [52]. Classically, the age at which HCC
develops is closely related to the age of acquisition of infection with
hepatitis and to the rate of viral replication [5]. In a case of an
early infection with HBV and an active viral replication (e.g. East
Asia), the age-specific distribution of HCC starts to increase at the
age of 50 without reaching a plateau [5]. In the case of a later
infection with HBV and a rapid decline of viral replication after
adolescence (e.g. West Africa), the age-specific distribution of
HCC represents a single peak starting between the ages of 45 and
plateauing thereafter [5,23]. In cases where HBV infection occurs
in adulthood, the HCC is rarely developed before the age of 50
years and the highest age-specific incidence rates are observed in
people over the age of 75 years [5]. None of these age distribution
patterns were observed for the Peruvian patients admitted at
INEN (Figure 1B). Moreover, the HCC etiology appears to be
Figure 3. Regional disparities in mean age of Peruvian patients
with HCC. The map was generated using the incidence rates of
patients admitted at INEN with HCC between 1997 and 2010. The
regions are classified as follow: (1) Amazonas (N = 20; mean age:
36.2620.3); (2) Ancash (N = 117; 49.7622.3); (3) Apurimac (N = 121;
31.6617.9); (4) Arequipa (N = 39; 56.6622.3); (5) Ayacucho (N = 161;
39.5620.6); (6) Cajamarca (N = 36; 50.2619.4); (7) Callao (N = 21;
52.3620.7); (8) Cuzco (N = 96; 33.8616.6); (9) Huancavelica (N = 32;
45.3623.9); (10) Huanuco (N = 68; 37.2620.8); (11) Ica (N = 43;
56.1619.3); (12) Junin (N = 180; 37.2619.9); (13) La Libertad (N = 68;
61.6619.3); (14) Lambayeque (N = 53; 56.8619.8); (15) Lima (N = 289;
48621.5); (16) Loreto (N = 21; 42.7620.8); (17) Madre de Dios (N = 2;
ND); (18) Moquegua (N = 5; ND); (19) Pasco (N = 29; 47.3619.6); (20)
Piura (N = 64; 58.2618.5); (21) Puno (N = 18; 55.4613.7); (22) San Martin
(N = 26; 43.3619.6); (23) Tacna (N = 4; ND); (24) Tumbes (N = 3; ND); and
(25) Ucayali (N = 25; 38.2618.8). Mean age intervals (years) are
established as follow: [31–38] (dark blue); [39–44] (light blue); [45–48]
(yellow); [49–52] (pink); and [53–62] (red). ND: Mean age was not
determined because the cohort of patients admitted at INEN during the
period and originating from these regions was too small. Administrative
regional limits from the Peruvian National Institute of Statistics and
Informatics (INEI).
doi:10.1371/journal.pone.0067756.g003
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different between the #44 and .44 groups, as the percentage of
people over age 44 infected with HBV was significantly lower than
in the #44 group (Figure 2B and Table 1). In addition, 50% of the
patients tested for hepatitis B infection were serologically negative
for HBsAg (Figure 2B and Table 1). Thus, while the role of HBV
infection as a major etiology of HCC development in Peru is
certain, it is not always present and appears, therefore, to be
insufficient in and of itself to explain the peculiarities of the
explosive tumor process as it is currently observed in Peru.
The particularity of the HCC epidemic is reinforced by the
geographical mapping of the patients according to their place of
origin. This process resulted in a striking geographical pattern in
which the younger patients were concentrated mostly in the inland
regions of the Andes, while the coastal regions provided HCC
cases with a more elevated age (Figure 3). As a consequence,
geographically neighbouring regions could display a 25 years
difference with regard to the mean age of HCC patients, as
observed for example in both Apurimac/Arequipa and Huanuco/
La Libertad tandems (Figure 3; region number 3/4 and 10/13,
respectively). At the moment, environmental or ethnogeographical
differences that may explain such dramatic variations in tumor
presentation remain unknown. In order to confirm this data, the
eventuality of a selection effect has to be discarded with a
prospective field study. Indeed, the lack of cancer surveillance at
the national level and the deficit of information about the patients’
clinical pathway prior to arrival at INEN prevent the accurate
evaluation of the real proportions of the #44 and .44 HCC
populations in Peru. Uncharacterized biasing parameter(s) may
result in enhancing the number of #44 patients hospitalized at
INEN. However, while such selection effect could have impacted
quantitatively the perception of the HCC context in our study, the
age-specific HCC pathophysiology in the #44 and .44 groups
clearly marked the distinction between these two subpopulations,
suggesting two different age-specific natural histories of HCC in
the Peruvian patient population.
The bimodal age-based distribution, the young age of a distinct
subgroup, the low rate of associated cirrhosis, the high seroAFP,
and the geographical clustering of the cases by age delineate an
unusual tumoral process ongoing in the Peruvian population.
These findings support the hypothesis that a singular risk factor,
environmental, infectious, or genetic, and possibly endemic to the
region is driving liver tumorigenesis in a significant proportion of
Peruvian HCC patients. Research programs embracing the
various aspects of this intriguing disease are required to decipher
the biological process ongoing in young Peruvian HCC patients
with the aim to generate novel prediction and prevention tools and
assays for the local public health authorities.
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